Regulatory 2022-12-06 | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients PDF Report Presentation Webcast
Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Presentation Webcast
2022-11-30 | ASCELIA PHARMA PRESENTS RESULTS OF ORVIGLANCE FOOD EFFECT STUDY AT RSNA 2022 SHOWING STRONG LIVER ENHANCEMENT BOTH WITH LIGHT MEAL AND IN FASTING CONDITION PDF Report Presentation Webcast
Regulatory 2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission PDF Report Presentation Webcast
2022-09-28 | Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study PDF Report Presentation Webcast
Regulatory 2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study PDF Report Presentation Webcast
2022-08-11 | Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting PDF Report Presentation Webcast
2022-06-20 | Ascelia Pharma appoints Déspina Georgiadou Hedin as new CFO PDF Report Presentation Webcast
2022-06-01 | Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference PDF PDF Report Presentation Webcast
2022-05-31 | Ascelia Pharma second US patent for Oncoral (oral irinotecan) strengthens coverage PDF Report Presentation Webcast
Regulatory 2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals PDF Report Presentation Webcast
2022-05-10 | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal PDF Report Presentation Webcast
Regulatory 2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 PDF Report Presentation Webcast
Regulatory 2022-04-11 | Ascelia Pharma publishes Annual Report for 2021 PDF Report Presentation Webcast
Regulatory 2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
